Approach to the Patient with Subclinical Cushing's Syndrome.

Approach to the Patient with Subclinical Cushing's Syndrome. Curr Pharm Des. 2020 Aug 13;: Authors: Ivović M, Marina LV, Šojat AS, Tančić-Gajić M, Arizanović Z, Kendereški A, Vujović S Abstract A growing number of patients with adrenal incidentalomas and subclinical Cushing's syndrome (SCS) led to a growing number of different guidelines, diagnostic and treatment recommendations. Excess cortisol secretion in patients with SCS is associated with a number of comorbidities, such as hypertension, dyslipidemia, type 2 diabetes mellitus and obesity, which in long-term increase mortality of these patients. Subtle cortisol secretion effects also bone health, quality of life and cause depression, but due to the unapparent clinical features, patients with SCS are often in risk between over and under treatment. The aim of this narrative review was to summarize the latest recommendations on the approach to the patient with subclinical Cushing's syndrome. PMID: 32787757 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - Category: Drugs & Pharmacology Authors: Tags: Curr Pharm Des Source Type: research